20.35
-0.02 (-0.10%)
| Previous Close | 20.37 |
| Open | 19.86 |
| Volume | 477,438 |
| Avg. Volume (3M) | 796,393 |
| Market Cap | 1,351,122,048 |
| Price / Sales | 178.33 |
| Price / Book | 1.92 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -9,027.19% |
| Diluted EPS (TTM) | -2.70 |
| Quarterly Revenue Growth (YOY) | 345.50% |
| Total Debt/Equity (MRQ) | 0.49% |
| Current Ratio (MRQ) | 21.67 |
| Operating Cash Flow (TTM) | -171.51 M |
| Levered Free Cash Flow (TTM) | -101.09 M |
| Return on Assets (TTM) | -16.88% |
| Return on Equity (TTM) | -23.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Celldex Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.13 |
|
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.32% |
| % Held by Institutions | 113.13% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 64.00 (Canaccord Genuity, 214.50%) | Buy |
| Median | 43.00 (111.30%) | |
| Low | 31.00 (Goldman Sachs, 52.33%) | Hold |
| Average | 45.20 (122.11%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 19.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Jun 2025 | 50.00 (145.70%) | Buy | 20.34 |
| 13 Jun 2025 | 50.00 (145.70%) | Buy | 21.26 | |
| Goldman Sachs | 09 May 2025 | 31.00 (52.33%) | Hold | 18.33 |
| Morgan Stanley | 09 May 2025 | 43.00 (111.30%) | Buy | 18.33 |
| 20 Mar 2025 | 46.00 (126.04%) | Buy | 19.88 | |
| UBS | 09 May 2025 | 38.00 (86.73%) | Buy | 18.33 |
| Canaccord Genuity | 28 Apr 2025 | 64.00 (214.50%) | Buy | 21.36 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |